Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2016 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's analyze the transcript. Management discusses several things: product launches (Radixact, Onrad), orders, backlog, revenue guidance, cost initiatives, etc. They mention specific customers: NHS supply chain in the U.K. (a multi-system order), a domestic multi-system order that was delayed but will be placed in fiscal 2017, and the first of those systems already in backlog. They also mention Japan's construction delays causing longer conversion times. They talk about Radixact reference sites, Onrad approval in China, and expect orders in second half. But does management narrate the counterparties' own trajectories as the driver of the company's coming activity? For example, they mention the NHS order as a large order, but they don't describe NHS's own expansion plans or program build-out. They mention the domestic customer that will place several orders in fiscal 2017, but again, they don't describe that customer's own growth trajectory. They mention Japan's construction delays, but that's about timing, not about the customer's expansion. They mention Radixact reference sites, but those are the company's own installations, not counterparties' trajectories. Onrad in China is about regulatory approval and expected orders, but they don't describe the Chinese market's own build-out. The essence of the question: Does management speak about counterparties' business as though it were part of its own? They do mention specific customers and orders, but they don't describe those customers' own ramps, launches, or scaling. They talk about the company's own product launches and selling efforts. The forward account is largely about the company's own actions: product launches, cost initiatives, sales efforts, and market conditions. They mention macro trends like global radiotherapy capacity needs, but that's broad market, not specific counterparties. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.